Clinical Trial Update: Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients [Phase 2]

View source ↗

Summary

A completed Phase II multi-center trial comparing MER-101 20 mg tablets to intravenous zoledronic acid (Zometa) 4 mg in bisphosphonate-naive men with hormone-re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• MER-101
• Zometa (Zoledronic acid)

Snippet

Sponsor: Merrion Pharmaceuticals, LLC | Conditions: Hormone-Refractory Prostate Cancer | Phase 2 | Status: COMPLETED